Our Products

Our products support the health of patients in the areas of maternal and women's health, anemia management and cancer supportive care. More

Research & Growth

We recognize the immense value of clinical research and are committed to investing in it to expand the body of knowledge in our therapeutic areas and advance potential future health innovations for patients. More

News

AMAG Announces First Patient Enrolled in Phase 2b/3a Digoxin Immune Fab Study...

AMAG Announces First Patient Enrolled in Phase 2b/3a Digoxin Immune Fab Study Conducted by Velo Bio

WALTHAM, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that Velo Bio, LLC has enrolled the first patient More

Working at AMAG

“The team that I have the pleasure to work with and the families that I have the pleasure to serve every day inspire and motivate me to do the best that I can for them.”

Kristen Swingle
Vice President of Laboratory Operations